Listen
(3 min)
yuri cortez/Agence France-Presse/Getty ImagesThe latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0803 GMT – CSPC Pharmaceutical Group’s growth visibility for next year appears clouded to UOB Kay Hian analysts Carol Dou and Sunny Chen. The Chinese pharma company’s nine-month finished drugs segment revenue fell 17.2% on year, compressing its gross margin significantly to 65.6% compared with 70.5% in the same period a year ago, they say in a note. While the company maintains its 2026 revenue growth outlook, the analysts expect China’s volume-based procurement policy for drugs to weigh on growth. Two potential out-licensing deals may also be delayed due to changing market dynamics, according to CSPC’s management. UOB KH cuts its rating on CSPC to hold from buy and trims its target to HK$8.50 from HK$12.00. Shares gain 3.0% to HK$7.79. ([email protected])
Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
